Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy.
Beyranvand Nejad E, Labrie C, Abdulrahman Z, van Elsas MJ, Rademaker E, Kleinovink JW, van der Sluis TC, van Duikeren S, Teunisse AFAS, Jochemsen AG, Oosting J, de Miranda NFCC, Van Hall T, Arens R, van der Burg SH. Beyranvand Nejad E, et al. Among authors: van elsas mj. J Immunother Cancer. 2020 Sep;8(2):e001326. doi: 10.1136/jitc-2020-001326. J Immunother Cancer. 2020. PMID: 32873723 Free PMC article.
Future Challenges in Cancer Resistance to Immunotherapy.
van Elsas MJ, van Hall T, van der Burg SH. van Elsas MJ, et al. Cancers (Basel). 2020 Apr 10;12(4):935. doi: 10.3390/cancers12040935. Cancers (Basel). 2020. PMID: 32290124 Free PMC article. Review.
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Beyranvand Nejad E, Labrie C, van Elsas MJ, Kleinovink JW, Mittrücker HW, Franken KLMC, Heink S, Korn T, Arens R, van Hall T, van der Burg SH. Beyranvand Nejad E, et al. Among authors: van elsas mj. J Immunother Cancer. 2021 Apr;9(4):e002460. doi: 10.1136/jitc-2021-002460. J Immunother Cancer. 2021. PMID: 33879600 Free PMC article.
NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division.
Borst L, Sluijter M, Sturm G, Charoentong P, Santegoets SJ, van Gulijk M, van Elsas MJ, Groeneveldt C, van Montfoort N, Finotello F, Trajanoski Z, Kiełbasa SM, van der Burg SH, van Hall T. Borst L, et al. Among authors: van elsas mj. Int J Cancer. 2022 Feb 15;150(4):688-704. doi: 10.1002/ijc.33859. Epub 2021 Nov 10. Int J Cancer. 2022. PMID: 34716584 Free PMC article.
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.
van Elsas MJ, van der Schoot JMS, Bartels A, Steuten K, van Dalen D, Wijfjes Z, Figdor CG, van Hall T, van der Burg SH, Verdoes M, Scheeren FA. van Elsas MJ, et al. Int J Mol Sci. 2022 Aug 5;23(15):8707. doi: 10.3390/ijms23158707. Int J Mol Sci. 2022. PMID: 35955841 Free PMC article.
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, Tonea R, Ovcinnikovs V, Lloyd K, Schuurman J, Riesenfeld SJ, Gajewski TF, de Miranda NFCC, van Hall T, van der Burg SH. van Elsas MJ, et al. Cancer Cell. 2024 Jun 10;42(6):1032-1050.e10. doi: 10.1016/j.ccell.2024.04.011. Epub 2024 May 16. Cancer Cell. 2024. PMID: 38759656 Free article.